Invent Medic’s product Efemia bladder support to be evaluated by potential distributor in Germany
Invent Medic announces that a potential distributor in Germany has decided to conduct an internal evaluation of the company’s medical technology product Efemia bladder support. The potential distributor is focused on urology-related products and pharmaceuticals and has a large number of customers in the German health care sector.
To facilitate a thorough evaluation of Efemia, an agreement has been signed that grants the potential distributor access to clinical data and product samples in different sizes.
The parties have been discussing a potential collaboration regarding Efemia for some time as there is a mutual interest in getting leading urology-related products into the hands of women in Europe.
“Even though we are initially focusing on launching Efemia in Sweden and the Nordic region, we are already planning our upcoming expansion in the rest of Europe. It is therefore exciting to take this important step towards signing a distribution agreement for Germany, which is the largest European market for medical technology products,” says Invent Medic’s CEO Karin Bryder.
For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com
This information is information that Invent Medic Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at on December 11, 2018.
About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.